Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1379)	9/20/2002 10:41:30 AM
From: tuck	Read Replies (1) \| Respond to of 3158

Consolidation continues to be led by the penny biotechs, and the trend of merging with privately held companies a la Microcide also continues: >>DALLAS, Sept 20 (Reuters) - Biotechnology company Exegenics Inc. (NasdaqNM:EXEG - News) said on Friday it agreed to merge with privately held Innovative Drug Delivery Systems Inc., in a move to speed commercialization of drugs in development. Under the terms of the deal, the companies will complete a stock swap in which one share of IDDS common stock will be exchanged for 3.132 shares of Exegenics common stock, which closed Thursday at 76 cents per share. Representatives from both companies were not immediately available to comment. Upon the closing of the merger, Exegenics will issue about 48.4 million shares of common stock, and will issue up to 11.7 million additional shares of common stock upon the exercise of outstanding IDDS options and warrants, in exchange for all of IDDS' outstanding equity interests. Mark Rogers, who is now chairman and chief executive of IDDS, will be named executive chairman of the combined company and Ronald Goode, currently Exegenics' president and CEO, will continue as president and CEO. In May, Exegenics said its agreement with Bristol-Myers Squibb was ending, stopping payments to Exegenics for a process to make cancer treatment paclitaxel, leading to an undisclosed number of job cuts.<< Now INCY munching RIGL, for a wild example, might be a worthy next step. Actually, INCY might be able to afford someone with a later stage program if they're going to insist on developing drugs. Cheers, Tuck